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Enteric fever is a major human infectious disease since centuries, surviving in conditions of poor sanitation, crowding, and social chaos [1]. It is caused by Salmonella 
typhi and Salmonella paratyphi A, B, and C. The crude incidence 
of typhoid fever in Southeast Asia is 110/1 lakh persons per year. 
Thus, India is among the high incidence countries for typhoid 
fever [2]. India and Pakistan account for a very high incidence of 
typhoid fever compared to other Southeast Asian countries such 
as Vietnam, Indonesia, and China [3].
Chloramphenicol, ampicillin, and trimethoprim-
sulfamethoxazole were initially used for the management of 
typhoid fever. In the late 1980s, there was widespread emergence 
of multidrug-resistant (MDR) S. typhi to all three drugs [4]. Later 
in the 1990s, high-level ciprofloxacin-resistant enteric fever 
evolved in Asian countries, including India [1,2,5-10]. In recent 
years, the third-generation cephalosporins have been used in 
fluoroquinolone-resistant areas, but resistance is also emerging 
to extended-spectrum cephalosporin [7,11]. An Indian study 
reported that 2% of Salmonella enterica isolates were resistant 
to the third-generation cephalosporins [12]. Until now, there 
are a few reports of extended-spectrum beta-lactamase (ESBL) 
producers in S. typhi and S. paratyphi A. This type of resistance 
being transferable, the major risk would be its transfer to S. typhi 
and S. paratyphi A. Their overuse in outpatient settings can 
induce and select strains with ESBLs, early reports of which are 
emerging from the Indian subcontinent [10,13,14].
Azithromycin, a broad spectrum azilide, has shown promise in 
the treatment of typhoid fever. It is an attractive alternative to the 
cephalosporin used in view of its single daily dosing, oral route, 
possibility of use in β-lactam allergic patients, and lower cost. In vitro, 
azithromycin has a minimum inhibitory concentration (MIC) range of 
4–16 μg/ml against S. typhi, suggesting that the drug has limited utility 
for the treatment of typhoid fever [15]. A rise in MIC over the years 
has been attributed to irrational prescription for minor community-
acquired upper respiratory, ear, and sinus infections [4,5,16-18]. In 
enteric fever, its role needs to be appreciated, as it is very effective 
in removing intracellular salmonellae, defervescence is rapid, 
gastrointestinal carriage is eradicated and, in particular, it represents a 
potential alternative in the pediatric population for whom quinolones 
are contraindicated [4].
There are reports of 12% Salmonella isolates resistant to 
azithromycin from a multicenter trial in India [16]. Another risk 
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factor to add on is that the isolates from Southern Asia showed 
increased MICs for ciprofloxacin and azithromycin in 21.4% of 
the isolates, which stresses the fact that azithromycin has to be 
used with caution in areas with high resistance and decreased 
susceptibility to ciprofloxacin [19]. Hence, the aim of this study 
was to determine the in vitro MIC patterns of azithromycin for 
the treatment of enteric fever in an endemic region reporting 
an increase in ciprofloxacin resistance and a raising ceftriaxone 
resistance. We also planned to determine if there is a correlation 
between ciprofloxacin and azithromycin susceptibility pattern 
among the study population.
MATERIALS AND METHODS
This retrospective study was conducted at a tertiary care hospital, 
Bengaluru, India, between June 2012 and June 2016. Case records 
of 363 children in the age group of 0–18 years diagnosed with 
proven enteric fever were reviewed. The list of children whose 
blood serology, i.e., Widal test and blood cultures were positive 
for S. typhi or S. paratyphi was retrieved from the microbiology 
laboratory records. Their respective case records were retrieved 
for verifying the clinical symptoms and diagnosis. Children with 
clinical symptoms and signs of fever, anorexia, lethargy, abdominal 
discomfort, nausea, vomiting, hepatomegaly, splenomegaly, and 
loose stools/constipation, which are compatible with enteric fever 
and isolation of S. typhi or S. paratyphi A, B, or C from blood 
culture were included in the study. Those children who were 
diagnosed based only on above clinical symptoms and signs with 
positive serologic tests such as Widal and typhidot/typhidot M 
along with negative blood cultures for S. typhi or S. paratyphi 
were excluded from the study.
Blood culture was done by BacT/Alert 3D system and 
serotypes were identified by biochemical tests after performing 
a Gram stain and subculture on blood agar and MacConkey agar. 
They were also identified by Vitek method. The sensitivity to 
ampicillin, cotrimoxazole, chloramphenicol, nalidixic acid, and 
ceftriaxone was interpreted by Kirby-Bauer method using Clinical 
and Laboratory Standards Institute (CLSI) guidelines 2016 [20]. 
The disc strength of 10 μg, 1.25/23.7 μg, 30 μg, 30 μg, and 30 μg 
was used with inhibition zone diameter of ≤13, ≤10, ≤12, ≤13, 
and ≤19 was considered as sensitive for the above antibiotics, 
respectively.
The MIC was determined against, azithromycin and 
ciprofloxacin by Etest. MIC of ≤0.06, 0.12–0.5, and ≥1 
to ciprofloxacin disc of 5 μg/ml was considered sensitive, 
intermediate sensitive, and resistant, respectively, according to 
the CLSI 2016. However, ciprofloxacin (cipro) MIC of ≤1 and ≥4 
was considered as sensitive and resistant, respectively, according 
to the CLSI guidelines 2011; till, the new guidelines 2016 
were available. MIC of ≤16 and ≥32 was considered sensitive 
and resistant, respectively, for azithromycin disc of 15 μg/ml. 
Azithromycin MIC ≥16 was considered resistant according to 
BSAC guidelines when CLSI guidelines were not available for 
azithromycin before 2016.
The data were analyzed by descriptive univariate analysis. 
Azithromycin sensitivity was analyzed using time-trend analysis.
RESULTS
Of the 363 blood isolates of Salmonella, 280 were S. enterica 
serovar typhi (77.14%) and 83 were serovar paratyphi A strains 
(22.86%). Among these, 361 (99.44%), 357 (98.34%), and 
360 (99.17%) were sensitive to first line antityphoid drugs, 
i.e., ampicillin, cotrimoxazole, and chloramphenicol, respectively. 
343 (94.49%) were nalidixic acid-resistant (NAR) Salmonella and 
remaining 20 (5.51%) were nalidixic acid-sensitive (NAS). Of 
the 272 (74.93%) isolates which showed reduced susceptibility 
to ciprofloxacin, 29 (7.98%) were resistant and 243 (66.66%) 
were intermediately sensitive to ciprofloxacin which is less 
than the NAR Salmonella (94.49%). As per definition, only 
one (0.27%) of the Salmonella isolates was MDR, i.e. resistant 
to ampicillin, chloramphenicol, and cotrimoxazole. The MDR 
isolate was S. enterica serotype typhi and it was also NAR 
Salmonella. 82 (98.7%) strains of serotype Paratyphi A were also 
NAR Salmonella, only one was NAS. All the 363 isolates had 
maintained 100% sensitivity to ceftriaxone (Fig. 1).
In our study, all the 363 Salmonella isolates were sensitive to 
azithromycin (MIC breakpoint ≤16 μg/ml). Azithromycin MICs 
were in the range of 0.064–12 µg/ml among the 363 isolates 
(Fig. 2). The distribution of azithromycin MICs of S. enterica 
typhi and paratyphi A peaked at 1, 2, and 1.5 µg, respectively. 
Trend analysis showed no increasing MIC over time for all isolates 
or for S. enterica serovar typhi or S. paratyphi, individually. Only 
5 (18.5%) of the isolates which were resistant to ciprofloxacin 
had MIC >4 μg/ml to azithromycin, and none were resistant to 
azithromycin (Fig. 3).
DISCUSSION
We found that S. enterica isolates at the place of study were 100% 
sensitive to azithromycin. Thus, azithromycin can still be used 
as a safe alternative for oral therapy of enteric fever in the area 
of study as opposed to few reports of increasing azithromycin 
resistance from India. Furthermore, there has been no increasing 
Figure 1: Resistance pattern among Salmonella typhi and Salmonella 
paratyphi isolates. Ampi: Ampicillin, Cotri: Cotrimoxazole, 
Chloram: Chloramphenicol, MDR: Multidrug resistance, 
Cipro: Ciprofloxacin, NAR: Nalidixic acid-resistant, Ceftri: Ceftriaxone
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trend of resistance for azithromycin in the past 4 years. These 
results were consistent with the results from study at Pakistan by 
Butt et al., in 2011, and from Egypt by Girgis et al., in 1999 [4,21].
Irrational use of azithromycin in URI and LRI in the 
community can induce resistance to this wonder drug. Also of 
interest is the recent report of azithromycin treatment failure 
following its use in a shigellosis outbreak in Paris, which is linked 
to plasmid-mediated resistance to macrolides [22]. It is quite 
possible that such resistance could be transmitted to Salmonella 
spp. and the above scenario could facilitate this occurrence. In 
previous studies by Butler et al. from India in 1999 and Hassing 
et al. from the Netherlands during 1999–2012 reported that 12% 
of isolates were resistant to azithromycin and 16.1% of isolates 
had high MIC (≥16 μg/ml) for azithromycin, respectively [16,19]. 
A recent study from Delhi has also detected increasing resistance 
to azithromycin from 2.8% to 17.6% and from 3.6% to 25% in S. 
typhi and S. paratyphi A isolates [12].
However, in the murine typhoid model, azithromycin given 
once daily was highly effective in clearing the infection, and this 
activity was attributable to the remarkable property of intracellular 
concentration of azithromycin in macrophages (>100 times 
the concentrations in serum) [23]. In Bangladesh, Islam et al. 
studied in vitro and in vivo response to azithromycin and found 
that 97.6% of azithromycin sensitive cases showed clinical 
improvement and 77.8% of azithromycin-resistant cases showed 
improvement. Clinical improvement of patients with azithromycin 
in azithromycin-resistant cases raises question about the in vitro 
sensitivity of Salmonella to azithromycin [24]. It has also been 
suggested that azithromycin is better for treating typhoid in resistant 
cases than both fluoroquinolone and ceftriaxone. Azithromycin 
significantly reduces relapse rate compared with ceftriaxone [25].
Hassing et al. reported that percentages of elevated MICs 
for azithromycin (≥16 μg/ml) were highest for isolates acquired 
in regions that had concurrent high proportions of isolates with 
decreased susceptibility or resistance to ciprofloxacin. In isolates 
acquired in countries from Southern Asia, increased MICs for 
ciprofloxacin and increased MICs for azithromycin were observed 
in 21.4% (18/84 isolates) of the isolates [19]. In the present study, 
18.5% (5/27 isolates) of the ciprofloxacin-resistant isolates had 
MIC ≥4 μg/ml for azithromycin but within 12 μg/ml MIC which 
is sensitive. Hence, there has not been any increased MIC for 
azithromycin in ciprofloxacin-resistant isolates. This suggests that 
there is no correlation between ciprofloxacin and azithromycin 
susceptibility and azithromycin can be used judiciously when 
the need arises, without fear of increased chances of resistance 
among ciprofloxacin-resistant isolates in the area of study.
There has been 100% sensitivity to ceftriaxone in the past 
4 years. Furthermore, there is resurgence of susceptibility to 
the first-line antityphoid drugs to the tune of 98–99%; hence, it 
can be a good option for alternative drugs for enteric fever in 
the era of limited number of new antibiotics with increasing 
antimicrobial resistance. The MDR S. typhi has reduced 
drastically to 0.27% which is a good indication to recycle the old 
drugs. With the development of resistance reported in few studies 
to ceftriaxone [13,14], the first-line drugs can be considered as 
the treatment option. However, there was a high prevalence of 
NAR Salmonella in the study population, of which the majority 
was among S. paratyphi A. 98.2% of S. paratyphi isolates were 
NAR. This stresses that fluoroquinolone should be avoided in 
enteric fever in spite of it being a very effective drug.
The limitation of the study was that the study was a 
retrospective study; hence, the in vivo response to the above drugs 
was not assessed. Therefore, a prospective study on response to 
azithromycin and ciprofloxacin and other antityphoid drugs 
would be required to confirm the findings from the present 
study. Azithromycin should be used cautiously and judiciously 
not only in enteric fever but also in many other infections such 
as upper and lower respiratory infections. A regular survey of 
local antibiogram patterns is necessary to monitor the antibiotic 
susceptibility trends and thus guide in appropriate therapy and 
management.
CONCLUSION
S. typhi continues to remain susceptible to azithromycin and the 
third-generation cephalosporin. There is no increasing trend in 
Figure 2: Distribution of azithromycin minimum inhibitory 
concentrations from 2012–2016. In this bar diagram, X- and Y-axis 
represents the MIC for azithromycin and number of Salmonella 
isolates, respectively
Figure 3: Comparison of azithromycin minimum inhibitory 
concentrations (MICs) with ciprofloxacin MIC.  – – –: Azithromycin 
MIC ≥4 μg/ml, – . – . –: Ciprofloxacin MIC ≥1 μg/ml. The 
Y-axis represents the MIC and X-axis is the 27 isolates of 
Salmonella enterica which are resistant to ciprofloxacin
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resistance to azithromycin over the years. Hence, azithromycin can 
be used safely in the area of study for enteric fever. Furthermore, 
azithromycin can be used safely in children with ciprofloxacin-
resistant isolates as there has not been any significant correlation 
between ciprofloxacin resistance and high azithromycin MICs.
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